VistaGen Therapeutics Inc
NASDAQ:VTGN
Operating Margin
VistaGen Therapeutics Inc
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
Country | Company | Market Cap |
Operating Margin |
||
---|---|---|---|---|---|
US |
V
|
VistaGen Therapeutics Inc
NASDAQ:VTGN
|
89.2m USD |
-7 567%
|
|
FR |
![]() |
Pharnext SCA
OTC:PNEXF
|
6T USD |
-17 527%
|
|
US |
![]() |
Abbvie Inc
NYSE:ABBV
|
369.8B USD |
31%
|
|
US |
![]() |
Amgen Inc
NASDAQ:AMGN
|
158.4B USD |
31%
|
|
US |
U
|
US BioTec Inc
OTC:USBC
|
184.3B USD | N/A | |
US |
![]() |
Gilead Sciences Inc
NASDAQ:GILD
|
142.9B USD |
38%
|
|
US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-370%
|
|
US |
![]() |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
101.6B USD |
39%
|
|
AU |
![]() |
CSL Ltd
ASX:CSL
|
104.9B AUD |
26%
|
|
US |
![]() |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
63.4B USD |
29%
|
|
US |
![]() |
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
59.9B USD |
-7%
|
VistaGen Therapeutics Inc
Glance View
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing and commercializing new generation medications that go beyond the current standard of care for anxiety, depression, and other central nervous system (CNS) disorders. The company is headquartered in South San Francisco, California and currently employs 31 full-time employees. The company went IPO on 2010-10-18. The firm is engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system (CNS). The firm's pipeline includes PH94B, a neuroactive nasal spray with potential to treat multiple anxiety disorders that is preparing for Phase III clinical trial for social anxiety disorder (SAD), PH10, a neuroactive nasal spray that is planning for Phase 2b development as a stand-alone treatment for depressive disorder (MDD), and AV-101 which the Company is developing for the treatment of depressive disorder (MDD), suicidal ideation, neuropathic pain, levodopa-induced dyskinesia (LID) and epilepsy. In addition, the Company has developed a human pluripotent stem cell (hPSC) technology platform, CardioSafe 3D, to predict potential heart toxicity of new chemical entities (NCEs).
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on VistaGen Therapeutics Inc's most recent financial statements, the company has Operating Margin of -7 566.5%.